Then it appears that a combination strategy with some newly approved agents (such as kinase inhibitors or BCL2 inhibitors) and selective targeting by functionalized nanoparticles may open up important opportunities to cure more patients suffering from AML, ALL, and CLL. Here, BCL2 is linked to acute lymphoblastic leukemia.